IL297206A - Crystalline forms of (9r, 135s)-13- {4-[5-chloro-2-(4-chloro-1h,2,3- triazol- 1-yl)phenyl] -6-oxo- 1,6-dihydropyrimidine - 1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15- tetraazatricyclo [ 12.3.1.02 6] octadeca- 1(18), 2(6), 4, 14, 16- pentaene -8-one - Google Patents
Crystalline forms of (9r, 135s)-13- {4-[5-chloro-2-(4-chloro-1h,2,3- triazol- 1-yl)phenyl] -6-oxo- 1,6-dihydropyrimidine - 1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15- tetraazatricyclo [ 12.3.1.02 6] octadeca- 1(18), 2(6), 4, 14, 16- pentaene -8-oneInfo
- Publication number
- IL297206A IL297206A IL297206A IL29720622A IL297206A IL 297206 A IL297206 A IL 297206A IL 297206 A IL297206 A IL 297206A IL 29720622 A IL29720622 A IL 29720622A IL 297206 A IL297206 A IL 297206A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- infrared
- spectrum
- ray diffraction
- crystalline form
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063008161P | 2020-04-10 | 2020-04-10 | |
| PCT/US2021/026663 WO2021207659A1 (en) | 2020-04-10 | 2021-04-09 | Crystalline forms of (9r, 135s)-13- {4-[5-chloro-2-(4-chloro-1h,2,3- triazol- 1 -yl)phenyl] -6-oxo- 1,6-dihydropyrimidin- 1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15- tetraazatricyclo [ 12.3.1.02·6] octadeca- 1(18), 2(6), 4, 14, 16-pentaen-8-one |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL297206A true IL297206A (en) | 2022-12-01 |
Family
ID=75690727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL297206A IL297206A (en) | 2020-04-10 | 2021-04-09 | Crystalline forms of (9r, 135s)-13- {4-[5-chloro-2-(4-chloro-1h,2,3- triazol- 1-yl)phenyl] -6-oxo- 1,6-dihydropyrimidine - 1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15- tetraazatricyclo [ 12.3.1.02 6] octadeca- 1(18), 2(6), 4, 14, 16- pentaene -8-one |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230151010A1 (https=) |
| EP (1) | EP4132930A1 (https=) |
| JP (2) | JP2023521411A (https=) |
| KR (1) | KR20230008742A (https=) |
| CN (1) | CN115916780A (https=) |
| AU (1) | AU2021253946A1 (https=) |
| BR (1) | BR112022020243A2 (https=) |
| CA (1) | CA3179957A1 (https=) |
| CL (1) | CL2022002786A1 (https=) |
| CO (1) | CO2022016067A2 (https=) |
| IL (1) | IL297206A (https=) |
| MX (1) | MX2022012523A (https=) |
| PE (1) | PE20231071A1 (https=) |
| WO (1) | WO2021207659A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA71692A (fr) | 2022-08-01 | 2025-05-30 | Bristol-Myers Squibb Company | Utilisation de milvexian pour le traitement ou la prévention d'un accident vasculaire cérébral ischémique |
| KR20250136432A (ko) | 2023-02-06 | 2025-09-16 | 브리스톨-마이어스 스큅 컴퍼니 | 밀벡시안 제약 조성물 |
| WO2025224678A1 (en) | 2024-04-25 | 2025-10-30 | Assia Chemical Industries Ltd. | Solid state forms of milvexian and process for preparation thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201908467RA (en) * | 2014-01-31 | 2019-10-30 | Bristol Myers Squibb Co | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors |
| NO2721243T3 (https=) * | 2014-10-01 | 2018-10-20 | ||
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
-
2021
- 2021-04-09 IL IL297206A patent/IL297206A/en unknown
- 2021-04-09 EP EP21722085.4A patent/EP4132930A1/en active Pending
- 2021-04-09 PE PE2022002222A patent/PE20231071A1/es unknown
- 2021-04-09 BR BR112022020243A patent/BR112022020243A2/pt unknown
- 2021-04-09 MX MX2022012523A patent/MX2022012523A/es unknown
- 2021-04-09 KR KR1020227039277A patent/KR20230008742A/ko active Pending
- 2021-04-09 CN CN202180039763.5A patent/CN115916780A/zh active Pending
- 2021-04-09 JP JP2022562082A patent/JP2023521411A/ja active Pending
- 2021-04-09 WO PCT/US2021/026663 patent/WO2021207659A1/en not_active Ceased
- 2021-04-09 AU AU2021253946A patent/AU2021253946A1/en active Pending
- 2021-04-09 CA CA3179957A patent/CA3179957A1/en active Pending
- 2021-04-09 US US17/995,848 patent/US20230151010A1/en active Pending
-
2022
- 2022-10-07 CL CL2022002786A patent/CL2022002786A1/es unknown
- 2022-11-09 CO CONC2022/0016067A patent/CO2022016067A2/es unknown
-
2025
- 2025-12-17 JP JP2025260150A patent/JP2026048873A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4132930A1 (en) | 2023-02-15 |
| BR112022020243A2 (pt) | 2022-11-22 |
| JP2026048873A (ja) | 2026-03-17 |
| PE20231071A1 (es) | 2023-07-17 |
| AU2021253946A1 (en) | 2022-12-15 |
| WO2021207659A1 (en) | 2021-10-14 |
| CO2022016067A2 (es) | 2023-01-26 |
| CL2022002786A1 (es) | 2023-04-14 |
| CN115916780A (zh) | 2023-04-04 |
| MX2022012523A (es) | 2022-11-07 |
| JP2023521411A (ja) | 2023-05-24 |
| US20230151010A1 (en) | 2023-05-18 |
| CA3179957A1 (en) | 2021-10-14 |
| KR20230008742A (ko) | 2023-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9920034B2 (en) | Crystalline forms of a factor XIa inhibitor | |
| US20230151010A1 (en) | Crystalline forms of (9r, 135s)-13- {4-[5-chloro-2-(4-chloro-1h,2,3- triazol- 1 -yl)phenyl] -6-oxo- 1,6-dihydropyrimidin- 1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15- tetraazatricyclo [ 12.3.1.0 2·6] octadeca- 1(18), 2(6), 4, 14, 16-pentaen-8-one | |
| JP2019517461A (ja) | Ｎ−［（２，６−ジフルオロ−３−メトキシフェニル）メチル］−３−（メトキシメチル）−１−（｛４−［（２−オキソピリジン−１−イル）メチル］フェニル｝メチル）ピラゾール−４−カルボキサミドの多形体 | |
| US20080188517A1 (en) | Crystalline forms of a factor xa inhibitor | |
| EP2691371B1 (en) | Benzoic acid salt of otamixaban | |
| US7388096B2 (en) | Crystalline forms of a factor Xa inhibitor | |
| HK1212333B (en) | Crystalline forms of a factor xia inhibitor | |
| HK1189584B (en) | Benzoic acid salt of otamixaban |